thalidomide has been researched along with Enlarged Liver in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We conducted a phase II, multicentre, study to investigate thalidomide in severely symptomatic indolent and aggressive systemic mastocytosis." | 5.17 | Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study. ( Barete, S; Bruneau, J; Canioni, D; Chaby, G; Chandesris, O; Damaj, G; Diouf, M; Dubreuil, P; Durieu, I; Grosbois, B; Gruson, B; Hermine, O; Lanternier, F; Larroche, C; Livideanu, C; Lortholary, O; Marolleau, JP; Sevestre, H, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gruson, B | 1 |
| Lortholary, O | 1 |
| Canioni, D | 1 |
| Chandesris, O | 1 |
| Lanternier, F | 1 |
| Bruneau, J | 1 |
| Grosbois, B | 1 |
| Livideanu, C | 1 |
| Larroche, C | 1 |
| Durieu, I | 1 |
| Barete, S | 1 |
| Sevestre, H | 1 |
| Diouf, M | 1 |
| Chaby, G | 1 |
| Marolleau, JP | 1 |
| Dubreuil, P | 1 |
| Hermine, O | 1 |
| Damaj, G | 1 |
1 trial available for thalidomide and Enlarged Liver
| Article | Year |
|---|---|
Thalidomide in systemic mastocytosis: results from an open-label, multicentre, phase II study.
Topics: Adult; Aged; Bone Marrow; Fatigue; Female; Fever; Gastrointestinal Diseases; Hematologic Diseases; H | 2013 |